PDE4A and chronic obstructive pulmonary disease: PDE4 inhibitors are new therapeutic options for COPD and a few new candidates, such as the dual PDE3/PDE4 inhibitor Ensifentrine, entered a phase 3 clinical trial, but none has yet reached the market.